XRCC3 Gene Polymorphism Is Associated with Survival in Japanese Lung Cancer Patients

International Journal of Molecular Sciences

Kayo Osawa¹  Chiaki Nakarai¹  Kazuya Uchino²  Masahiro Yoshimura²  Noriaki Tsubota³  Juro Takahashi¹ 

[1] Faculty of Health Sciences, Kobe University Graduate School of Health Sciences, Kobe 654-0142, Japan; E-Mails:;Department of General Thoracic Surgery, Hyogo Cancer Center, Akashi 673-0021, Japan; E-Mails:;Department of Thoracic Oncology, Hyogo College of Medicine, Nishinomiya 663-8501, Japan; E-Mail:

关键词: gene polymorphisms;    lung cancer;    survival;    DNA repair;    XRCC3;   

DOI  :  10.3390/ijms131216658

来源: mdpi

【 摘 要 】

We focused on OGG1 Ser326Cys, MUTYH Gln324His, APEX1 Asp148Glu, XRCC1 Arg399Gln, and XRCC3 Thr241Met and examined the relationship between the different genotypes and survival of Japanese lung cancer patients. A total of 99 Japanese lung cancer patients were recruited into our study. Clinical data were collected, and genotypes of the target genes were identified by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Survival analysis to verify the impact of these gene polymorphisms on the clinical outcome of lung cancer showed that lung squamous cell carcinoma patients with the Thr/Met genotype at XRCC3 had a significantly shorter survival time than those with the Thr/Thr genotype (13 months versus 48 months; log-rank test, p < 0.0001). Cox regression analysis showed that the carriers of XRCC3 genotypes were at a significantly higher risk [adjusted hazard ratio (HR) = 9.35, 95% confidence interval (CI) = 2.52–34.68, p = 0.001; adjusted HR = 9.05, 95% CI = 1.89–44.39, p = 0.006]. Our results suggest that XRCC3 Thr241Met may act as a favorable prognostic indicator for lung squamous cell carcinoma patients.

【 授权许可】

CC BY   
© 2012 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland.